Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "certificate of analysis/1000"

Looking for quality documents?
external link icon
Repligen Hires Jon K. Snodgres as Chief Financial Officer
WALTHAM, Mass., July 15, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Jon K. Snodgres has been named its Chief Financial Officer. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course of five years with Maquet, Mr. Snodgres contributed to the company's growth from niche status to a diversified business generating over $1 billion in annual revenue. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific where he was Vice President of Finance for the Laboratory Products Group. At both Maquet and Thermo Fisher, Mr. Snodgres held key responsibility for numerous acquisitions and restructuring programs. He was also integral to the success of pricing and facility optimization programs that drove substantial earnings improvements. "I would like to welcome Jon to the Repligen management team," said Walter C. Herlihy, President and Chief Executive Officer of
external link icon
Repligen Appoints Jason K. Garland as Chief Financial Officer
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed Jason K. Garland as Chief Financial Officer (“CFO”), effective September 25, 2023. Mr. Garland is joining Repligen from his most recent role with medical device outsource (MDO) manufacturer Integer Holdings Corporation (“Integer”), where he served for nearly five years (2018-2023) as Executive Vice President and CFO. He succeeds retiring CFO Jon K. Snodgres, who joined the Company in June 2014 and will continue in a full-time advisory role until his October 6, working closely with Mr. Garland to ensure a smooth transition. In this strategic CFO role, Mr. Garland will act as a key partner to the business, with responsibility for all corporate finance and audit functions, capital markets and M&A transactions, financial planning and analysis, budgeting and risk management. He brings to the
corporate icon
PATsmart™ FlowVPX® System
Continuous in-line concentration measurement for real-time process control Designed for GMP environments, the PATsmart™ FlowVPX® spectrophotometer delivers continuous, in-line concentration measurement during downstream processing, providing real-time data to actively control the process as it runs. This level of control is made possible by Variable Pathlength Technology (VPT), which enables accurate, dilution-free concentration measurement across development, scale-up, and GMP manufacturing.
news icon
Repligen strengthens downstream offering with $200m ARTeSYN acquisition
news icon
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
external link icon
Repligen Corporation Names Tony Hunt as Next Chief Executive Officer
WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders. "Under Walter's leadership, Repligen has been transformed from a therapeutics company that produced bioprocessing products into a focused bioprocessing industry leader, providing high-value consumable products for biological manufacturers and creating substantial value for our stockholders," commented Karen A. Dawes, Chair of the Board of Repligen. "Walter has been a major force in building this outstanding company, and the Board and I, on behalf of the stockholders, thank Walter for his dedication, vision, and leadership." Ms. Dawes continued, "We are delighted to promote
external link icon
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the
external link icon
Repligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer
WALTHAM, Mass., May 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation, a life sciences company focused on the manufacture and commercialization of bioprocessing products, today announced the appointment of Tony J. Hunt to the newly created position of Chief Operating Officer. Mr. Hunt was most recently President, BioProduction at Life Technologies, a global life sciences company whose acquisition by Thermo Fisher Scientific was completed earlier this year. At Life Technologies, Mr. Hunt played a key role in the development and growth of the company's bioprocessing business, where he focused on expanding the upstream Gibco® cell culture franchise and building the downstream purification and analytics franchises. Mr. Hunt is an accomplished life sciences industry veteran who will oversee commercial and manufacturing operations for Repligen. "We welcome Tony to the Repligen management team, where his industry knowledge and understanding of bioproduction market drivers will help guide the
event icon
What Bioprocessing Professionals Think About the KrosFlo® KR2i Tangential Flow Filtration System
Supporting academics, start-ups, CDMOs, and large biotech companies alike, the KrosFlo® KR2i tangential flow filtration (TFF) system continues to be a staple in the industry after 10+ years of ongoing innovation. Have you ever wondered why it’s gained such a following and if it’s a fit for your unique process? What happens when you hand over the mic to people who use this tried-and-true system every single day? In this webinar, ReciBioPharm and KBI Biopharma will pull back the curtain on their real-world experiences with the KrosFlo KR2i TFF system. From accelerating development timelines to solving unexpected bottlenecks, they’ll share the wins, the surprises, and the lessons learned along the way. Whether you're evaluating new TFF systems, looking to switch platforms, or already using the KrosFlo KR2i system and wanting to optimize your process, this is your chance to hear directly from real-world users. Key Takeaways: Performance highlights and challenges from real-world applications. Best practices and lessons learned from experienced users. Tips for achieving consistent and scalable TFF results.
publications icon
Accelerating analytical testing for GMP plasmid production
The challenges associated with gene therapy bioprocessing are numerous and burdensome, from scalability to Cost of Goods control, and from ensuring quality/consistency to accessing sufficient capacity and expertise. The consensus of opinion in the field is that a largely or fully automated process based upon a single, easy-to-use platform would be optimal, as would the adoption of single-use technology. The majority of challenges that arise with testing of gene therapy materials relate to time and accuracy. The CTech™ SoloVPE® and FlowVPX® slope spectroscopy technology is specifically designed to address these very issues Speaker: Paul Mania
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support